Impact on survival of different treatments for myelodysplastic syndromes (MDS)

Leukemia Research

Volumn 33, Issue 8, 2009, Pages 1024-1028

  Nachtkamp, Kathrin ^a   Kündgen, Andrea ^a   Strupp, Corinna ^a   Giagounidis, Aristoteles ^b   Kobbe, Guido ^a   Gattermann, Norbert ^a   Haas, Rainer ^a   Germing, Ulrich ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b ST JOHANNES HOSPITAL   (Germany)

Author keywords

Allogeneic transplantation; Antithymocyte globulin; Induction chemotherapy; Low dose Ara C; Myelodysplastic syndromes; Prognosis; Thalidomide; Valproic acid

Indexed keywords

ANTHRACYCLINE; CYTARABINE; THALIDOMIDE; THYMOCYTE ANTIBODY; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER RISK; CANCER THERAPY; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PALLIATIVE THERAPY; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REGISTER; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AGED; ANTILYMPHOCYTE SERUM; CYTARABINE; DISEASE-FREE SURVIVAL; ENZYME INHIBITORS; FEMALE; GERMANY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; THALIDOMIDE; TRANSPLANTATION, HOMOLOGOUS; VALPROIC ACID;

EID: 67349089233     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.12.019     Document Type: Article

References (20)

1. Bennett J.M. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 72 (2000) 131-133
2. Greenberg P., Cox C., Le Beau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
3. Germing U., Gattermann N., Strupp C., Aivado M., and Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 24 (2000) 983-992
4. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20 May (10) (2002) 2429-2440
5. Kantarjian H., Issa J.P., Rosenfeld C.S., Bennett J.M., Albitar M., DiPersio J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106 April (8) (2006) 1794-1803
6. Saba H.I., Bennett J.M., Rosenfeld C.S., Issa J.P., de Castro C., DiPersio J.F., et al. Advanced myelodysplastic syndromes (MDS): patient subset results of a phase III trial comparing decitabine (DAC) vs. supportive care (SC). Leuk Res 29 1 (2005) S69-S70
7. Fenaux P., Mufti G.J., Santini V., et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): results of the AZA-001 phase III study. Blood (ASH Annual Meeting Abstracts) 110 (2007, November) 817
8. Appelbaum F.R., and Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia 12 September (Suppl. 1) (1998) S25-S29
9. Runde V., de Witte T., Arnold R., Gratwohl A., Hermans J., van Biezen A., et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 21 February (3) (1998) 255-261
10. Lim Z.Y., Killick S., Germing U., Cavenagh J., Culligan D., Bacigalupo A., et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict haematological responses to anti-thymocyte globulin. Leukemia 21 July (7) (2007) 1436-1441
11. Stadler M., Germing U., Kliche K.O., Josten K.M., Kuse R., Hofmann W.K., et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 18 March (3) (2004) 460-465
12. Kuendgen A., Schmid M., Knipp S., Hildebrandt B., Fox F., Strupp C., et al. Results of a phase II trial with valproic acid (VPA) alone or in combination with all-trans-retinoic acid (ATRA) in 71 patients with myelodysplastic syndromes or SAML/MDS. Leuk Res 29 Suppl. 1 (2005) S66
13. Kuendgen A., Strupp C., Aivado M., Bernhardt A., Hildebrandt B., Haas R., et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 104 September (5) (2004) 1266-1269
14. Strupp C., Germing U., Aivado M., Misgeld E., Haas R., Gattermann N., et al. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 16 January (1) (2002) 1-6
15. Raza A., Meyer P., Dutt D., Zorat F., Lisak L., and Nascimben du Randt M. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98 August (4) (2001) 958-965
16. Candoni A., Raza A., Galili N., Simeone E., Buttignol S., Silvestri F., et al. Thalidomide alone or in combination with other agents for the treatment of myelodysplastic syndromes (MDS). Leuk Res 31 May (Suppl. 1) (2007) S119
17. Musto P., Falcone A., Sanpaolo G., and Bodenizza C. Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes. Leuk Res 30 April (4) (2006) 385-388 [epub 2005 October 10]
18. Zwierzina H., Suciu S., Loeffler-Ragg J., Neuwirtova R., Fenaux P., Beksac M., et al. EORTC Leukemia Cooperative Group. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. Leukemia 19 11 (2005) 1929-1933
19. Aul C., Gattermann N., Heyll A., Germing U., Derigs G., and Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 6 January (1) (1992) 52-59
20. Knipp S., Hildebrand B., Kündgen A., Giagounidis A., Kobbe G., Haas R., et al. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer 110 July (2) (2007) 345-352